Key Highlights

  • Biogen traded at US$222.15, against a consensus target of US$229.84.
  • The median target of US$235 implies roughly +5.8% upside from the current price.
  • Targets span US$157 to US$300, framing the range of analyst opinion.
  • The consensus implies N/A upside, reflecting the balance of current analyst views.

Biogen (NASDAQ:BIIB) traded at US$222.15 as of 8 October 2026, against an analyst consensus price target of US$229.84, an implied upside of approximately N/A.

What Is the Latest Analyst Price Target?

According to a data provider screener as at 8 October 2026, the mean analyst price target is $229.84, while the median is higher at $235. The range is wide: the lowest target is $157 and the highest is $300. The share price of $222.15 therefore sits comfortably inside that band, well above the bottom and a long way beneath the top. The gap between mean and median suggests a handful of cautious forecasts are dragging the average down, with most targets clustered nearer $235.

What Are Analysts Saying?

The provider's overall analyst consensus rating is Buy. so What the target range itself shows is a divided but broadly constructive picture: the low target is roughly 29% beneath the current price, whereas the high target is about 35% above it. That asymmetry, with a median above the mean, hints that the more optimistic views carry real weight, even if the average implies only modest potential upside.

What Could Help the Stock Reach the Price Target?

Biogen has positioned itself as a specialist in neurological and neurodegenerative disease, with a portfolio that includes long-established multiple sclerosis treatments alongside newer therapies. If analysts prove correct, the path to the target runs through successful commercialisation of newer products, steady cash generation from the established Franchise and disciplined spending. Pipeline progress in areas such as Alzheimer's disease and rare neurological conditions could also lift sentiment, since the market tends to reward credible late-stage assets. Partnerships and bolt-on acquisitions have historically been part of the company's playbook, and well-judged deals could refresh the growth outlook.

What Could Prevent the Stock Reaching the Target?

The risks are structural as well as company-specific. Older multiple sclerosis drugs face generic and biosimilar competition, which can erode Revenue faster than new launches replace it. Neurology is also a notoriously difficult field, where clinical trial setbacks and slower-than-hoped product uptake are common. Pricing pressure from payers and governments adds a further headwind, and a P/E of 39.5 leaves limited room for disappointment. Because the shares already trade close to the mean target, even a modest stumble could push the price below the consensus rather than toward it.

What Should Investors Watch Next?

Investors will want to follow the next quarterly results and any updated company guidance, paying attention to sales trends for the newer launches and the pace of decline in legacy products. Clinical readouts and regulatory decisions across the neurology pipeline are the other obvious catalysts, as are any Business development announcements. Pricing policy developments affecting drugmakers more broadly may also influence sentiment, as may changes in analyst targets themselves after results.

The Case Analysts Are Making on Biogen

Biogen (BIIB) was priced at US$222.15 against a consensus target of US$229.84, an implied upside of approximately N/A. The median target of US$235 and the range of US$157 to US$300 frame the debate among analysts.